Neupro (rotigotine) is a prescription drug that’s used to treat Parkinson’s disease and restless legs syndrome. The drug comes as a patch that’s applied to the skin. It’s usually applied once per day.
Rotigotine 2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours; transdermal patch; contains sulfites. Neupro is a transdermal patch containing rotigotine, a D3/D2/D1 dopamine agonist. The mechanism of action ...
Latest safety and efficacy results for rotigotine in the treatment of moderate to severe restless legs syndrome presented at major North American neurology congress Brussels (Belgium), 13 April 2010, ...
The World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome The only transdermal dopamine agonist*1 system, which helps ...
Atlanta, April 14th, 2010 – Evidence of Neupro® (Rotigotine Transdermal System) improving motor as well as non-motor symptoms of Parkinson's disease was presented at the 62nd American Academy of ...
ATLANTA, Dec. 13 /PRNewswire/ -- UCB announced today that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as a treatment for moderate-to-severe restless legs syndrome (RLS) has ...
UCB has already made progress in reformulation and remains committed to bringing Neupro® to U.S. patients suffering from Parkinson's disease and Restless Leg Syndrome Brussels (Belgium) - April 23, ...
Atlanta, April 13th, 2010 – New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome (RLS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results